Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines

Journal of Biosciences

Volumn 37, Issue 1, 2012, Pages 73-84

  Mahoney, Simon ^a   Arfuso, Frank ^b   Rogers, Pierra ^b   Hisheh, Susan ^c   Brown, David ^d   Millward, Michael ^e   Dharmarajan, Arun ^b  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Novogen Limited   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Apoptosis; isoflavone; phenoxodiol; prostate

Indexed keywords

CASPASE 3; IDRONOXIL; ISOFLAVONE;

APOPTOSIS; CANCER; DISEASE TREATMENT; ENZYME ACTIVITY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER STAGING; CELL ASSAY; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE DEPOLARIZATION; MITOCHONDRION; PROSTATE CANCER;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; ISOFLAVONES; MALE; MITOCHONDRIAL MEMBRANES; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 84859776394     PISSN: 02505991     EISSN: 09737138     Source Type: Journal    
DOI: 10.1007/s12038-011-9170-6     Document Type: Article

References (35)

1. Aguero MF, Facchinetti MM, Sheleg Z and Senderowicz AM 2005 Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res. 65 3364-3373 (Pubitemid 40524621)
2. Alhasan SA, Pietrasczkiwicz H, Alonso MD, Ensley J and Sarkar FH 1999 Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr. Cancer 34 12-19 (Pubitemid 29382910)
3. Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, Rutherford T and Mor G 2006 Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 106 599-608 (Pubitemid 43157623)
4. Axanova L, Morre DJ and Morre DM 2005 Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors. Cancer Lett. 225 35-40 (Pubitemid 40732766)
5. Beecher GR 2003 Overview of dietary flavonoids: nomenclature, occurrence and intake. J. Nutr. 133 3248S-3254S (Pubitemid 37222252)
6. Brown JM and Attardi LD 2005 The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer 5 231-237 (Pubitemid 40314954)
7. Brown JM and Wilson G 2003 Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? Cancer Biol. Ther. 2 477-490
8. Brown JM and Wouters BG 1999 Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59 1391-1399 (Pubitemid 29160097)
9. Brown DM, Kelly GE and Husband AJ 2005 Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer. Mol. Biotechnol. 30 253-270 (Pubitemid 41272813)
10. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T and Korsmeyer SJ 2001 BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8 705-711 (Pubitemid 32946946)
11. Constantinou AI, Mehta R and Husband A 2003 Phenoxodiol, a novel isoflavone derivative, inhibits dimethylbenz[a]anthracene (DMBA)-induced mammary carcinogenesis in female Sprague- Dawley rats. Eur. J. Cancer 39 1012-1018 (Pubitemid 36428635)
12. Cory S and Adams JM 2002 The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2 647-656 (Pubitemid 37328916)
13. De Luca T, Morre DM, Zhao H and Morre DJ 2005 NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. Biofactors 25 43-60
14. Dharmarajan AM, Goodman SB, Tilly KI and Tilly JL 1994 Apoptosis during functional corpus luteum regression: evidence of a role for chorionic gonadotropin in promoting luteal cell survival. Endocrine J. 2 295-303 (Pubitemid 2065935)
15. Feldman BJ and Feldman D 2001 The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1 34-45 (Pubitemid 33741879)
16. Fojo T and Bates S 2003 Strategies for reversing drug resistance. Oncogene 22 7512-7523 (Pubitemid 37487173)
17. Gamble JR, Xia P, Hahn CN, Drew JJ, Drogemuller CJ, Brown D and Vadas MA 2005 Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int. J. Cancer 118 2412-2420
18. Georgaki S, Skopeliti M, Tsiatas M, Nicolaou KA, Ioannou K, Husband A, Bamias A, Dimopoulos MA, et al. 2009 Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo. J. Cell Mol. Med. 13 3929-3938
19. Gleave M, Miyake H and Chi K 2005 Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother. Pharmacol. 56 47-57
20. Hong SJ, Dawson TM and Dawson VL 2004 Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. 25 259-264 (Pubitemid 38553828)
21. Hsing AW, Tsao L and Devesa SS 2000 International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 85 60-67
22. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ 2005 Cancer statistics 2005 CA Cancer J. Clin. 55 10-30
23. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, Brown D and Mor G 2003 Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 22 2611-2620 (Pubitemid 36605609)
24. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ and Schlesinger PH 2000 Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 7 1166-1173 (Pubitemid 32042223)
25. McPherson RA, Galettis PT and de Souza PL 2009 Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. Br. J. Cancer 100 649-655
26. Middleton E Jr, Kandaswami C and Theoharides TC 2000 The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 52 673-751
27. Morre DJ, Chueh PJ, Yagiz K, Balicki A, Kim C and Morre DM 2007 ECTO-NOX target for the anticancer isoflavene phenoxodiol. Oncol. Res. 16 299-312 (Pubitemid 47488074)
28. Puthalakath H and Strasser A 2002 Keeping killers on a tight leash: transcriptional and post-translational control of the proapoptotic activity of BH3-only proteins. Cell Death Differ. 9 505-512 (Pubitemid 34521178)
29. Ruth AC and Roninson IB 2000 Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res. 60 2576-2578 (Pubitemid 30318226)
30. Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, Garg M, Kamsteeg M, et al. 2004. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol. Res. 14 567-578 (Pubitemid 40178958)
31. Scherr DS, Vaughan ED Jr, Wei J, Chung M, Felsen D, Allbright R and Knudsen BS 1999 BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J. Urol. 162 12-16; discussion 16-17
32. Silasi DA, Alvero AB, Rutherford TJ, Brown D and Mor G 2009 Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin. Pharmacother. 10 1059-1067
33. Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM and Hussain A 2006 Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin. Cancer Res. 12 169-174 (Pubitemid 43166191)
34. Tannock IF and Lee C 2001 Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br. J. Cancer 84 100-105 (Pubitemid 32102512)
35. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, et al. 2004 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl. J. Med. 351 1502-1512 (Pubitemid 39315317)